Additional Supporting information may be found in the online version of this article.

JBMR_267_sm_SuppFig1.tif5544KSupplemental Figure 1. (A) Northern blots of Nell-1, Ocn and Gapdh using total RNA of whole head tissues from newborn mice with the indicated Runx2 genotypes. Notably, a single band of 3.5 kb Nell-1 or 0.7 kb Ocn transcript was detectable in Runx2+/+ and Runx2+/− tissues, but not in Runx2−/− tissue, respectively. (B) Runx2+/−/CMV-Nell-1 P21 mice demonstrating significantly increased calvarial bone formation relative to the Runx2+/− animal on microCT (arrows in green). (C) Three major MAPK pathways including ERK, JNK and p38 were tested for their activation status upon rNell-1 stimulation in Runx2+/+ NMCCs. The phosphorylation pattern of both ERK1/2 and JNK1 with rNell-1 stimulation was similar to that seen in Runx2+/− cells. Unexpectedly, the level of p38 and p-p38 in Runx2+/+ cells was low while high levels of p-38 and p-p38 were observed in Runx2−/− and Runx2+/− cells under the current study condition in Figure 4i. (D) Graph showing dose dependent rNell-1 stimulation of 6OSE activity in both Runx2+/− and Runx2−/− cells with significant increase from 100 ng/ml to 1600 ng/ml rNell-1 (* p < 0.05 and ** p < 0.01). (E) Cell proliferation assay using MTT at different time points after MAPK inhibitors treatment (* p < 0.05, ** p < 0.01 and NS: no significant difference).
JBMR_267_sm_SuppFig2.tif7322KSupplemental Figure 2. Flow cytometry analysis of apoptosis with Annexin V and PI staining on NMCCs treated with MAPK inhibitors. (A) Distribution of apoptotic and non-apoptotic cells. (B) Relative percentage of early and late apoptotic cells among different treatment groups. FAS: Fas-induced apoptosis as positive control; NT: no treatment control; Ap: apoptosis.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.